John M. Powers

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

The paper identifies a broadly neutralizing antibody targeting the S2 subunit of sarbecoviruses, revealing a conserved site of vulnerability in the spike protein.

This study shows that SARS-CoV-2 with impaired nsp14-exonuclease activity has reduced replication, fitness, and pathogenesis, but remains viable in some conditions.

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This paper develops a mouse model of SARS-CoV-2 BA.5 infection that induces fibrotic lung disease and tertiary lymphoid structures, enabling study of acute and post-acute sequelae of COVID-19.

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.